DailyComposite
Advertisement
MIT Tech Review

Mind-altering substances are (still) falling short in clinical trials

TechDaily Composite

This week I want to look at where we are with psychedelics, the mind-altering substances that have somehow made the leap from counterculture to major focus of clinical research. Compounds like psilocybin—which is found in magic mushrooms—are being explored for all sorts of health applications, including treatments for depression, PTSD, addiction, and even obesity. Over…

M

Source

MIT Tech Review

Read full article at MIT Tech Review

Opens original article in a new tab

Advertisement

Related Tech Stories

TechDaily Composite
The Verge

This is Microsoft’s plan to fix Windows 11

Microsoft has faced a breakdown of trust in Windows 11 and a backlash over AI additions to its operating system in recent months. After promising to rebuild trust in Windows earlier this year, Microsoft's Windows chief, Pavan Davuluri, is now revealing the company's plan to fix Windows 11 - and there are a lot of changes on the way. "Over the past several months, the team and I have spent a great deal of time analyzing your feedback," says Davuluri in a blog post committing to Windows quality im

Read more →
TechDaily Composite
The Verge

Trump takes another shot at dismantling state AI regulation

The Trump administration on Friday unveiled its new legislative blueprint for AI regulation, and the seven-point plan includes a clear message: The federal government should avoid many AI regulations beyond a set of child safety rules, and it should bar states from messing with the "national strategy to achieve global AI dominance." The plan advises Congress to protect minors using AI services with more safeguards and take action to attempt to prevent electricity costs from spiking due to AI in

Read more →
Advertisement